ERBB2 and breast cancer: In the near future, with the introduction of perioperative immunological treatments, novel CDK4-specific inhibitors, and more targeted endocrine therapies, a significant proportion of previously high-risk HR+/HER2- breast cancers will likely show a relatively favorable prognosis.